Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Why is Aclaris Therapeutics Stock Trading Lower on Monday?

Aclaris Therapeutics Inc. (NASDAQ:ACRS) CEO Neal Walker affirmed on Monday that the clinical-stage biopharmaceutical company will maintain its core development priorities despite missing primary and secondary endpoints in a Phase 2 atopic dermatitis study. Walker emphasized that Aclaris remains committed to advancing its oral kinase inhibitors and bispecific antibody programs toward major…

Why is Aclaris Therapeutics Stock Trading Lower on Monday?

Aclaris Therapeutics stock prices declined on Monday as the company reported disappointing results from a Phase 2 trial of its experimental drug for atopic dermatitis. CEO Neal Walker assured investors that the biopharmaceutical firm would remain focused on advancing its core development programs, despite missing primary and secondary endpoints in the trial.

Bosakitug, the drug in question, demonstrated some positive pharmacodynamic effects in patients, indicating strong engagement with its target. Aclaris also launched a new Phase 2b trial for a potential treatment of lichen planus, a chronic inflammatory skin condition. The company's stock dropped 13.52% in premarket trading following the report.

Written by urgent.news from Benzinga's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at benzinga.com →

More in Finance & Markets

US Justice Department, Wall Street Groups Challenge Illinois Crypto Tax

The US Department of Justice, major financial industry associations and decentralized finance (DeFi) companies have filed briefs in an Illinois court challenging the state's Digital Asset Tax Act.

  • U.S. DOJ and financial groups challenge Illinois Digital Asset Tax Act
  • Act imposes 0.2% tax on digital asset services, raising compliance concerns

More from Monday 16 November →